[EN] COMPOUNDS USEFUL AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS [FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR APPARENTÉ AU RÉCEPTEUR DES RÉTINOÏDES GAMMA
[EN] COMPOUNDS USEFUL AS RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS [FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR APPARENTÉ AU RÉCEPTEUR DES RÉTINOÏDES GAMMA
Novel retinoid-related orphan receptor gamma (RORϒ) modulators and their use in the treatment of diseases mediated by RORϒ provided by the present invention.
Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors
作者:Yonghui Wang、Wei Cai、Guifeng Zhang、Ting Yang、Qian Liu、Yaobang Cheng、Ling Zhou、Yingli Ma、Ziqiang Cheng、Sijie Lu、Yong-Gang Zhao、Wei Zhang、Zhijun Xiang、Shuai Wang、Liuqing Yang、Qianqian Wu、Lisa A. Orband-Miller、Yan Xu、Jing Zhang、Ruina Gao、Melanie Huxdorf、Jia-Ning Xiang、Zhong Zhong、John D. Elliott、Stewart Leung、Xichen Lin
DOI:10.1016/j.bmc.2013.12.021
日期:2014.1
Novel series of N-(5-(arylcarbonyl) thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl) amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (ROR gamma t) inhibitors. SAR studies of the ROR gamma t HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration. (C) 2013 Elsevier Ltd. All rights reserved.
METHODS OF TREATING OR PREVENTING BRAIN DAMAGE DUE TO HYPOXIC-ISCHEMIA
申请人:EMORY UNIVERSITY
公开号:US20160317473A1
公开(公告)日:2016-11-03
This disclosure relates to managing brain injury. In certain embodiments, this disclosure relates to methods comprising administering an effective amount of an inhibitor of sphingosine-1-phoshate signaling, an inhibitor of retinoic-acid-receptor-related orphan receptors α or γ, and/or an inhibitor of tPA microglial activation to a subject in need thereof. Typically, the subject is a neonate or a neonate born prematurely.